Genmab — Maj 2020
-
UPDATE 1-Roche, Novartis highlight intensifying rivalry in eye disease, MS https://www.reuters.com/article/roche-lucentis-port/update-1-roche-novartis-highlight-intensifying-rivalry-in-eye-disease-ms-idUSL8N2D90NH
-
@Pensionisten please stick with your sommerblomster and stop shaking that tree???
-
Lancet: Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30081-8/fulltext
-
and : Daratumumab: a game changer in myeloma therapy https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30105-8/fulltext#
-
Måske skal vi under 2000...
-
....og så kommer det igen. Er der nogen der ved noget...gevinsthjemtagning...eller noget helt tredje..;-)
-
here you can find the EAN Late-breaking Abstracts if you are interested in the Ofa abstracts (LB62, LB82 & LB129) pdf file https://www.ean.org/fileadmin/user_upload/ean/congress-2020/Present/Abstracts/Abstracts_LB_210x276_V2.pdf
-
Måske vi er ved at vende nu. Fut grønne i US, DAX op og i DK ser vi bl.a. rotation mod cykliske aktier. Alle lign Genmab falder i samme mønster. Ikke noget galt i at der tages gevinst. Den kommer højere. Markedet skal blot indstilles til det nye leje. Spgm er nu blot om vi siger 1/2 år eller 2 år før vi er væsentligt højere.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind